OncoScreen-CEA Rapid Test for Carcinoembryonic Antigen (CEA) – Colorectal, Breast, Lung, and Pancreatic Cancer Screening Overview:OncoScreen-CEA is a rapid diagnostic test developed by OncoFirm Diagnostics for the detection and monitoring of Carcinoembryonic Antigen (CEA), a well-established biomarker associated with colorectal cancer and other solid tumors, including breast, lung, and pancreatic cancers. Built on our advanced…
OncoScreen-PSA Rapid Test for Prostate-Specific Antigen (PSA) Detection Overview:OncoScreen-PSA is a fast, reliable, and easy-to-use rapid test for the detection of elevated Prostate-Specific Antigen (PSA) levels—an important biomarker in the early identification and monitoring of prostate cancer. Developed using OncoFirm’s advanced lateral flow assay (LFA) technology, this test provides results within 15 minutes, empowering healthcare…
OncoMultiDx Multiplex Rapid Test for Multi-Cancer Screening in a Single Assay Overview:OncoMultiDx is OncoFirm Diagnostics’ most advanced lateral flow assay, designed to detect multiple cancer types from a single sample—providing a comprehensive, rapid, and non-invasive cancer screening tool for clinical environments. Utilizing a proprietary combination of TF and Gal-GalNAc antigens, along with enhanced nanoparticle signal…
OncoScreen-B Rapid Test for Breast and Ovarian Cancer Detection Overview:OncoScreen-B is an advanced rapid diagnostic test developed by OncoFirm Diagnostics for the early detection of breast and ovarian cancers. Powered by proprietary lateral flow assay (LFA) technology, this test targets tumor-specific Thomsen-Friedenreich (TF) and Gal-GalNAc antigens, offering accurate, non-invasive cancer screening at the point of…